Atibuclimab Biosimilar - Research Grade

Atibuclimab Biosimilar - Research Grade, Human IgG4

Target: CD14.

Specificity: Detects human CD14. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Atibuclimab.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background: RUO atibuclimab is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis. It acts as a pattern recognition receptor for bacterial cell wall components in gram-positive and negative bacteria. CD14 antibody action stimulates a pro-inflammatory cytokine cascade often associated with inflammation in sepsis. Atibuclimab neutralization of this antibody results in the inhibition of TNF-a, IL-6 and IL-10, dampening systemic inflammatory responses. Atibuclimab also delays the release of sTNFR(1) and IL-1ra.

Concentration: 5mg/ml.

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE.

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

• Artikelnummer: ICH5016-100MG
• Hersteller: Ichorbio
• Hersteller Artikelnummer: ICH5016-100MG
• Green Labware: Nein
• Verpackungseinheit: 100mg
• Mengeneinheit: STK
• Reaktivität: Human
• Klonalität: Monoclonal
• Methode: Functional Assay
• Isotyp: Human IgG4